The Cancer Genome Atlas
The Cancer Genome Atlas (TCGA) is a project, first initiated in 2005, that aims to catalogue and discover major cancer-causing genomic alterations to create a comprehensive "atlas" of cancer genomic profiles. The project is funded by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), two of the National Institutes of Health (NIH).
History[edit]
The Cancer Genome Atlas was launched in 2005 as a joint effort between the NCI and NHGRI. The project was initially piloted with $50 million each from both institutes. The success of the pilot project, which focused on glioblastoma multiforme, ovarian serous cystadenocarcinoma, and lung squamous cell carcinoma, led to the continuation and expansion of TCGA.
Goals[edit]
The primary goal of TCGA is to improve the ability to diagnose, treat, and prevent cancer. It aims to do this through a better understanding of the genomic changes that occur in cancer. The project seeks to create a comprehensive "atlas" of cancer genomic profiles, which can be used by researchers and clinicians to develop more effective ways to diagnose and treat cancer.
Methodology[edit]
TCGA uses large-scale genome sequencing and bioinformatics to identify mutations in cancer. The project includes multiple types of data, including DNA sequence, copy number variation, DNA methylation, mRNA expression, miRNA expression, and protein expression. These data are made publicly available to the research community.
Impact[edit]
TCGA has significantly contributed to our understanding of cancer. The project has identified key mutations in many types of cancer, and has provided a wealth of data for researchers. The data from TCGA is being used to develop new diagnostic tests and treatments for cancer.
See also[edit]
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
